StoneX Sets $3 Target for Biofrontera Following Early FDA Approval of Ameluz

Key Facts

In a move reflecting the accelerating pace of clinical innovation, Biofrontera Inc. has secured early U.S. FDA approval for its drug Ameluz to treat superficial basal cell carcinoma (sBCC). The approval arrived ahead of schedule, marking a strategic milestone that significantly expands the company's commercial potential in the American dermatological oncology market. According to reports, this regulatory success strengthens the company's specialized product pipeline.

Following the news, StoneX reiterated a 'Speculative Buy' rating on BFRI shares, setting a price target of $3.00. Per market data, BFRI closed at $1.36 on September 14, 2026, having traded within a range of $1.36 to $1.57 during that session. The $3.00 target represents a significant premium over current levels, as analysts view the early approval as a major de-risking event that paves the way for enhanced revenue growth.

Looking ahead, investors will monitor BFRI's momentum toward the $3.00 target relative to its September 14, 2026 close of $1.36. With no major sector catalysts in the immediate economic calendar, market focus shifts to the commercial execution of the Ameluz rollout. Traders may look to the recent high of $1.57 as a key technical resistance level to clear in the near term.